Home About Press Employ Contact Spyglass Advanced Search
HHMI Logo
HHMI News
HHMI News
Scientists & Research
Scientists & Research
Janelia Farm
Janelia Farm
Grants & Fellowships
Grants & Fellowships
Resources
Resources
HHMI Bulletin
Currrent Issue Subscribe
Back Issues About the Bulletin
May '06
Features
divider
Cech
divider
Up Front
divider

Where the Antigens Aresmall arrow

divider

Evolution of a Dancesmall arrow

divider

A Few Good Neuronssmall arrow

divider

Whittling Thousands
to a Few


divider
Chronicle
divider
Perspectives
divider
Editor

Subscribe Free
Sign up now and receive the HHMI Bulletin by mail free.small arrow

UPFRONT: Whittling Thousands to a Few

PAGE 2 OF 2

To get around this problem, O'Shea and Shokat developed the first step of their method—a molecular trick that allows only the kinase of interest to grab the radioactive ATP. They added a chemical tab to radioactive ATP and engineered Pho85 to have a slot to match the chemical tab, making them fit together much like pieces of a jigsaw puzzle. So only the Pho85 is capable of transferring a radioactive phosphate to its proteins.

To understand the function...

But how to find those proteins that Pho85 controls in yeast cells? Step two: The team designed yeast proteins to have unique molecular "handles." These antigenlike handles can be snagged with an antibody that recognizes them specifically and pulled out of the extract by a method called tandem affinity purification (TAP). Within a yeast cell, only one type of protein out of the multitude present is marked with a TAP handle.

The researchers then created 4,250 yeast strains, all identical except for the unique TAP-handled protein each strain makes. This bevy of strains represents a large percentage of all the proteins a yeast cell makes—and that a kinase can act upon. The importance of making such strains, says O'Shea, was to keep the kinase in an environment close to its natural habitat, thereby reducing the possibility that the kinase would behave in any way different from normal.

After adding Pho85 to a mash of pooled yeast strains, the team pulled out all the proteins displaying a TAP handle. The ones that showed up with a dab of radioactivity—from Pho85—could be investigated further. O'Shea and Shokat found 24 proteins that came through the steps radioactive, spotlighting two dozen possible Pho85 substrates. As an added bonus, one of the proteins had been previously reported to be under Pho85's control, affirming the value of their method.

We think the trick...

Besides Pho85, Shokat has made more than 75 additional slotted kinases, 95 percent of which work well with the modified radioactive ATP. "We think the trick will be generalizable to almost every kinase," says Shokat. If so, this technique will help researchers move many kinases off the mystery list. grey bullet

dividers
PAGE 2 OF 2
small arrow Back
dividers
Download Story PDF
Requires Adobe Acrobat
Email This Story
The Big Picture
A FAMILY OF OVERACHIEVERS

Protein kinases belong to a very large family of enzymes. The human genome contains about 500 protein kinase genes, or about 2 percent of the total. Kinases play a major role in controlling many key activities of the cell and are particularly prominent in transmitting signals within a cell and in coordinating the steps of cellular replication.

A protein kinase modifies other proteins by chemically adding phosphate groups to them—a process called phosphorylation. The process usually results in a change in the target protein's activity, its location within the cell, or its interactions with other proteins. Each kinase can be a multi-tasker, having several substrates and acting as a substrate for other kinases.

Precise control of protein phosphorylation is critical to normal cell behavior. Uncontrolled kinase activity is a frequent cause of disease. For example, in cancer, kinase-mediated regulation of many aspects of cell growth, movement, and death is disrupted. For these reasons, compounds that inhibit the activity of protein kinases are being studied as therapeutic agents. In fact, some kinase inhibitors are already available for treating patients, including the two anticancer drugs Gleevec (imatinib mesylate) and Iressa (gefitinib).

dividers
Back to Topto the top
HHMI Logo

Home | About HHMI | Press Room | Employment | Contact

© 2012 Howard Hughes Medical Institute. A philanthropy serving society through biomedical research and science education.
4000 Jones Bridge Road, Chevy Chase, MD 20815-6789 | (301) 215-8500 | e-mail: webmaster@hhmi.org